ClinicalTrials.gg
TerminatedNCT00311311Updated Sep 23, 2013Results posted

Study Comparing Effect On Carotid Atherosclerosis Following Conversion From Tacrolimus To Sirolimus Post-Transplant In Kidney Transplant Patients

A Phase 3 interventional study of tacrolimus and mycophenolate mofetil in Atherosclerosis and Kidney Failure, sponsored by Pfizer. Terminated at 8 sites in 2 countries. Open to participants aged 35 Years and older. Per ClinicalTrials.gov, last updated 2013-09-23.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Why this study was terminated
See termination reason in detailed description.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
35 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 91 studies in Atherosclerosis with a site in Canada — 10 open to participants now, 17 under way, 9 of them phase 3. Atherosclerosis · Canada.

Enrollment
65th of 73
72 · median 440
Started
2006
with 2 others
Phase 3
31 of 91
2 open now
Registered
18th of 91
by date

Among the 91 studies in Atherosclerosis with a site in Canada, this one is the 65th largest by enrollment of the 73 interventional ones that give a count, is one of 3 that started in 2006, is one of 31 in phase 3, and was the 18th registered.

Atherosclerosis

1,519 studies on the registry are indexed under Atherosclerosis; 226 are open to participants now.

Browse Atherosclerosis studies →

Open to participants now

10 of the 91 studies in Atherosclerosis with a site in Canada are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 163 Atherosclerosis studies recruiting now, 85 (52%) set no upper age limit and 34 (21%) stop at 75 or younger; 16 take children under 18; 35 take healthy volunteers.

This study: 35 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 91 studies in Atherosclerosis with a site in Canada, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether immunosuppression by tacrolimus, mycophenolate mofetil, and prednisone compared to conversion to sirolimus, mycophenolate mofetil, and prednisone affect the progression of atherosclerosis in renal transplant recipients.

Read the detailed description

A decision to terminate the study was taken in November 2011 and a communication to that effect sent to all participating sites on November 18. All sites were asked to have patients returned to the sites and have all end of study procedures performed by Dec 31, 2011.

The decision to terminate this study was made following the conduct of an interim analysis which demonstrated that the study did not reach its primary endpoint. The termination of this study was not driven by any safety concerns and had no impact on subject safety and well-being.

03

Conditions studied

  • Atherosclerosis
  • Kidney Failure

Keywords

  • Kidney transplant
  • Renal transplant
  • Immunosuppression
  • Atherosclerosis
  • Graft Rejection
04

Who can participate

Ages eligible
35 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

At least one of the following characteristics:

  • History of dialysis for at least 3 years.
  • History of diabetes for at least 5 years.
  • Hypertension or ischemic nephropathy as a cause of the end stage renal disease or loss of the first transplant.
  • History of coronary artery disease, stroke, myocardial infarction, or amputation for vascular disease.

Exclusion criteria

Exclusion Criteria:

  • History of within the last 5 years (except adequately treated skin cancer).
  • Recipients of non-renal organ transplant.
  • Active gastrointestinal disease that may interfere with drug absorption.
  • Active , or C infection.
  • Women who are pregnant or breastfeeding.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
72 participants (actual)

Study arms

  • Active comparator
    1

    Tacrolimus + MMF + Steroids

    Drug: tacrolimus · Drug: mycophenolate mofetil · Drug: prednisone

  • Experimental
    2

    Tacrolimus + MMF + Steroids with conversion from Tacrolimus to Sirolimus at 3-4 months post-transplant

    Drug: sirolimus · Drug: tacrolimus · Drug: mycophenolate mofetil · Drug: prednisone

Interventions

  • The daily dosage and formulation for each study treatment will be chosen by the investigator as medically appropriate for each individual subject, in order to achieve the target levels specified in the protocol TAC should be initiated within 24 hours before or after transplantation or within 14 days of transplantation as per local standard of care and tapered to a target trough level of 3-10 ng/mL by the Pre-Conversion visit at month 3-4 post-transplantation. The target trough level of TAC will be maintained at 3-10 ng/mL through to the end of the study.

    Also known as: CNI

  • The daily dosage and formulation for each study treatment will be chosen by the investigator as medically appropriate for each individual subject, in order to achieve the target levels specified in the protocol MMF or MPS should be initiated within 24 hours before or after transplantation or within 14 days of transplantation per local standard of care and tapered to a minimum oral dose of MMF ≥ 500 mg/day or MPS ≥ 360 mg/day by the Pre-Conversion visit at month 3-4 post-transplantation. At the discretion of the investigator, MMF may be changed to MPS, or MPS may be changed to MMF. MMF is to be continued at ≥ 500 mg/day dose or MPS is to be continued at ≥ 360 mg/day dose through to the end of study.

    Also known as: MMF, MPS

  • The daily dosage and formulation for each study treatment will be chosen by the investigator as medically appropriate for each individual subject, in order to achieve the target levels specified in the protocol CCS should be initiated within 24 hours before or after transplantation or within 14 days of transplantation per local standard of care and tapered to a minimum of 5 mg/day of prednisone orally or the alternate day equivalent by the Pre-Conversion visit at month 3-4 post-transplant. Continue administration of prednisone as per local standard of care to a minimum dose of 2.5 mg/day or alternate day equivalent dose to the end of the study. Withdrawal of CCS is prohibited.

    Also known as: CCS

  • The daily dosage and formulation for each study treatment will be chosen by the investigator as medically appropriate for each individual subject, in order to achieve the target levels specified in the protocol. On study Day 1 Conversion, the daily dose of TAC will not be taken, and SRL is initiated as a single 5-10 mg loading dose, followed by 3 mg/day on subsequent days, adjusted to maintain a SRL target trough level of 8-15 ng/mL through to month 24 post-transplant, then 5-12 ng/mL to the end of month 36 post-transplant.

  • The daily dosage and formulation for each study treatment will be chosen by the investigator as medically appropriate for each individual subject, in order to achieve the target levels specified in the protocol TAC should be initiated within 24 hours before or after transplantation or within 14 days of transplantation as per local standard of care and tapered to a target trough level of 3-10 ng/mL by the Pre-Conversion visit at month 3-4 post-transplantation. Reintroduction of TAC or introduction of CsA is not permitted in the SRL Therapy group.

    Also known as: CNI

  • The daily dosage and formulation for each study treatment will be chosen by the investigator as medically appropriate for each individual subject, in order to achieve the target levels specified in the protocol MMF or MPS should be initiated within 24 hours before or after transplantation or within 14 days of transplantation per local standard of care and tapered to a minimum oral dose of MMF ≥ 500 mg/day or MPS ≥ 360 mg/day by the Pre-Conversion visit at month 3-4 post-transplantation. At the discretion of the investigator, MMF may be changed to MPS, or MPS may be changed to MMF. MMF is to be continued at ≥ 500 mg/day dose or MPS is to be continued at ≥ 360 mg/day dose through to the end of study.

    Also known as: MMF, MPS

  • The daily dosage and formulation for each study treatment will be chosen by the investigator as medically appropriate for each individual subject, in order to achieve the target levels specified in the protocol CCS should be initiated within 24 hours before or after transplantation or within 14 days of transplantation per local standard of care and tapered to a minimum of 5 mg/day of prednisone orally or the alternate day equivalent by the Pre-Conversion visit at month 3-4 post-transplant. Continue administration of prednisone as per local standard of care to a minimum dose of 2.5 mg/day or alternate day equivalent dose to the end of the study. Withdrawal of CCS is prohibited.

    Also known as: CCS

06

What researchers measure

Primary outcomes

  1. Annual Change Rate in Total Plaque Volume (TPV) From Pre-conversion Baseline to 12 Months Post-transplant

    Within-subject annual change rate in TPV in the left and right distal common carotid arteries from the pre-conversion baseline to 12 months post kidney transplant as determined by ultrasound. Annual change rate equals (=) (TPV at month 12 post-transplant minus \[-\] TPV at pre-conversion baseline) divided (/) by imaging interval in years. TPV is the sum of assessment in left and right distal common carotid arteries.

    Time frame: Pre-conversion baseline and 12 months post-transplant

  2. TPV at Pre-conversion Baseline

    TPV is the sum of the assessment in left and right distal common carotid arteries.

    Time frame: Pre-conversion baseline

Secondary outcomes

  1. Annual Change Rate in Carotid Intima Media Thickness (CIMT) From Pre-conversion Baseline at 12, 18, 24 and 36 Months Post-transplant

    Within-subject annual change rate in CIMT as determined by ultrasound. Mean CIMT=average of left CIMT and right CIMT. Annual CIMT Change Rate (mm/year) = (CIMT at Month x Post-transplant Visit - CIMT at Conversion Baseline) / Imaging interval in years.

    Time frame: Pre-conversion baseline, and 12, 18, 24 and 36 months post-transplant

  2. CIMT at Pre-conversion Baseline

    Mean CIMT=average of left CIMT and right CIMT.

    Time frame: Pre-conversion baseline

  3. Change From Pre-conversion Baseline in Carotid Plaque Roughness at 12 and 24 Months Post-transplant

    Carotid plaque roughness as determined by ultrasound. Change equals (=) value at post-transplant month x minus (-) pre-conversion baseline.

    Time frame: Pre-conversion baseline, 12, and 24 months post-transplant

  4. Change From Pre-conversion Baseline in Fasting Lipid Parameters at 12, 18, 24 and 36 Months Post-transplant

    Total Cholesterol (TC), Low Density Lipoprotein (LDL), High Density Lipoprotein (HDL) and Triglyceride (Tg) blood concentrations. Higher levels of TC, LDL and Tg are less desirable. Lower levels of HDL are less desirable. Change for each parameter = value at 12, 18, 24 and 36 months post-transplant - value at pre-conversion baseline.

    Time frame: Pre-conversion baseline, and 12, 18, 24 and 36 months post-transplant

  5. Change From Pre-conversion Baseline in Glucose at Months 12, 24 and 36 Post-transplant

    Fasting plasma glucose. Change = value at month x post-transplant - pre-conversion baseline values.

    Time frame: Pre-conversion baseline, 12, 24 and 36 months post-transplant

  6. Change From Pre-conversion Baseline in Insulin at Months 12, 24, and 36 Post-transplant

    Fasting insulin. Change = value at month x post-transplant - pre-conversion baseline.

    Time frame: Pre-conversion baseline, 12, 24 and 36 months post-transplant

  7. Change From Pre-conversion Baseline in Glycosylated Hemoglobin(HbA1C) at Months 12, 24, and 36 Post-transplant

    HbA1C, change = value at month x post-transplant - pre-conversion baseline.

    Time frame: Pre-conversion baseline, 12, 24 and 36 months post-transplant

  8. Change From Pre-conversion Baseline in Adiponectin at Months 12, 24 and 36 Post-transplant

    Adiponectin is a biomarker for cardiovascular disease and atherosclerosis risk. A higher level indicates less risk. Change = month x post-transplant values - pre-conversion baseline values.

    Time frame: Pre-conversion baseline, 12, 24 and 36 months post-transplant

  9. Change From Pre-conversion Baseline in High Sensitivity C-Reactive Protein (hsCRP) at Months 12, 24 and 36 Post-transplant.

    hsCRP is a biomarker of cardiovascular disease and atherosclerosis risk. A higher level indicates a greater risk. Change = month x post-transplant values - pre-conversion baseline values.

    Time frame: Pre-conversion baseline, 12, 24 and 36 months post-transplant

  10. Change From Pre-conversion Baseline in Tumor Necrosis Factor Alpha (TNF-alpha) at Months 12, 24 and 36 Post-transplant

    TNF-alpha is a biomarker for cardiovascular disease and atherosclerosis risk. A higher level indicates a greater risk. Change = month x post-transplant values - pre-conversion baseline values.

    Time frame: Pre-conversion baseline, 12, 24 and 36 months post-transplant

  11. Change From Pre-conversion Baseline in Endothelin-1 at Months 12, 24 and 36 Post-transplant

    Endothelin-1 is a biomarker for cardiovascular disease and atherosclerosis risk. A higher level indicates greater risk. Change = month x post-transplant values - pre-conversion baseline values.

    Time frame: Pre-conversion baseline, 12, 24 and 36 months post-transplant

  12. Change From Pre-conversion Baseline in Interleukin-6 (IL-6) at Months 12, 24 and 36 Post-transplant

    IL-6 is a biomarker for cardiovascular disease and atherosclerosis risk. A higher level indicates a greater risk. Change = month x post-transplant values - pre-conversion values.

    Time frame: Pre-conversion baseline, 12, 24 and 36 months post-transplant

  13. Change From Pre-conversion Baseline in Homocysteine at Months 12, 24 and 36 Post-transplant

    Homocysteine is a biomarker for cardiovascular disease and atherosclerosis risk. A higher level indicates a greater risk. Change = month x post-transplant values - pre-conversion baseline values.

    Time frame: Pre-conversion baseline, 12, 24 and 36 months post-transplant

  14. Change From Pre-conversion Baseline in Lipoprotein(a) at Months 12, 24 and 36 Post-transplant

    Lipoprotein(a) is a biomarker for cardiovascular disease and atherosclerosis risk. A higher level indicates a greater risk. Change = month x post-transplant values - pre-conversion baseline values.

    Time frame: Pre-conversion baseline, 12, 24 and 36 months post-transplant

  15. Change From Pre-conversion Baseline in Fibrinogen at Months 12, 24 and 36 Post-transplant

    Fibrinogen is a biomarker for cardiovascular disease and atherosclerosis risk. A higher level indicates a greater risk. Change = month x post-transplant values - pre-conversion baseline values.

    Time frame: Pre-conversion baseline, 12, 24 and 36 months post-transplant

  16. Change From Pre-conversion Baseline in Vitamin B12 at Months 12, 24 and 36 Post-transplant

    Vitamin B12 is a biomarker for cardiovascular disease and atherosclerosis risk. A lower level indicates a greater risk. Change = month x post-transplant values - pre-conversion values.

    Time frame: Pre-conversion baseline, 12, 24 and 36 months post-transplant

  17. Change From Pre-conversion Baseline in Uric Acid at Months 12, 24 and 36 Post-transplant

    Uric Acid is a biomarker for cardiovascular disease and atherosclerosis risk. A higher level indicates a greater risk. Change = month x post-transplant values - pre-conversion baseline values.

    Time frame: Pre-conversion baseline, 12, 24 and 36 months post-transplant

  18. Change From Pre-conversion Baseline in Folate at 12, 24 and 36 Months Post-transplant

    Folate is a biomarker for cardiovascular disease and atherosclerosis risk. A lower level indicates a greater risk. Change = month x post-transplant values - pre-conversion baseline values.

    Time frame: Pre-conversion baseline, 12, 24 and 36 months post-transplant

  19. Number of Participants Who Used Lipid Lowering Therapies

    Participants who reported "yes" for taking lipid lowering therapies as concomitant medication.

    Time frame: From consent to conversion, from conversion to Month 12, from Months 12 to 24, and from Months 24 to 36 post-transplant

  20. Number of Participants Who Used Anti-hypertensive Medications

    Participants who reported "yes" for taking anti-hypertensive medications as concomitant medication.

    Time frame: From consent to conversion, from conversion to Month 12, from Months 12 to 24, and from Months 24 to 36 post-transplant

  21. Annual Rate of Change in TPV From Pre-conversion Baseline to 18, 24 and 36 Months Post Transplant

    Within-subject annual change rate in TPV in the left and right distal common carotid arteries from the pre-conversion baseline to 18, 24 and 36 months post kidney transplant as determined by ultrasound. Annual change rate equals (=) (TPV at month 18, 24 and 36 post-transplant minus \[-\] TPV at pre-conversion baseline) divided (/) by imaging interval in years. TPV is the sum of assessment in left and right distal common carotid arteries.

    Time frame: Pre-conversion baseline, and 18, 24 and 36 months post-transplant

07

Results

Posted May 24, 2012

Participant flow

Participant flow — Overall Study
MilestoneTacrolimus Then Sirolimus With Mycophenolate/PrednisoneTacrolimus With Mycophenolate/Prednisone
Started3735
Completed2926
Not completed89
Withdrew: Adverse event32
Withdrew: Withdrawal by subject11
Withdrew: Noncompliance01
Withdrew: Study termination by sponsor34
Withdrew: Death10
Withdrew: Lack of ancillary assistance01

Outcome measures

PrimaryAnnual Change Rate in Total Plaque Volume (TPV) From Pre-conversion Baseline to 12 Months Post-transplant

Within-subject annual change rate in TPV in the left and right distal common carotid arteries from the pre-conversion baseline to 12 months post kidney transplant as determined by ultrasound. Annual change rate equals (=) (TPV at month 12 post-transplant minus \[-\] TPV at pre-conversion baseline) divided (/) by imaging interval in years. TPV is the sum of assessment in left and right distal common carotid arteries.

Time frame:
Pre-conversion baseline and 12 months post-transplant
Reported as:
Mean · millimeter cube/year (mmˆ3/year)
Annual Change Rate in Total Plaque Volume (TPV) From Pre-conversion Baseline to 12 Months Post-transplant
millimeter cube/year (mmˆ3/year)Tacrolimus Then Sirolimus With Mycophenolate/PrednisoneTacrolimus With Mycophenolate/Prednisone
Annual Change Rate in Total Plaque Volume (TPV) From Pre-conversion Baseline to 12 Months Post-transplant-49.31 ± 125.0380.66 ± 23.103
PrimaryTPV at Pre-conversion Baseline

TPV is the sum of the assessment in left and right distal common carotid arteries.

Time frame:
Pre-conversion baseline
Reported as:
Mean · mmˆ3
TPV at Pre-conversion Baseline
mmˆ3Tacrolimus Then Sirolimus With Mycophenolate/PrednisoneTacrolimus With Mycophenolate/Prednisone
TPV at Pre-conversion Baseline68.68 ± 116.57448.57 ± 72.207
SecondaryAnnual Change Rate in Carotid Intima Media Thickness (CIMT) From Pre-conversion Baseline at 12, 18, 24 and 36 Months Post-transplant

Within-subject annual change rate in CIMT as determined by ultrasound. Mean CIMT=average of left CIMT and right CIMT. Annual CIMT Change Rate (mm/year) = (CIMT at Month x Post-transplant Visit - CIMT at Conversion Baseline) / Imaging interval in years.

Time frame:
Pre-conversion baseline, and 12, 18, 24 and 36 months post-transplant
Reported as:
Mean · millimeter/year (mm/year)
Annual Change Rate in Carotid Intima Media Thickness (CIMT) From Pre-conversion Baseline at 12, 18, 24 and 36 Months Post-transplant
millimeter/year (mm/year)Tacrolimus Then Sirolimus With Mycophenolate/PrednisoneTacrolimus With Mycophenolate/Prednisone
Annual Change Rate at 12 months (n=16,28)0.048 ± 0.09770.012 ± 0.0732
Annual Change Rate at 18 months (n=15,26)0.041 ± 0.0641-0.0002 ± 0.0543
Annual Change Rate at 24 months (n=15,23)0.023 ± 0.06140.015 ± 0.0453
Annual Change Rate at 36 months (n=8,13)0.028 ± 0.0381-0.007 ± 0.0460
Statistical analysis
  • Tacrolimus Then Sirolimus With Mycophenolate/Prednisone vs Tacrolimus With Mycophenolate/Prednisone · ANCOVA · p = 0.0445 (P-value and 95% CI for least square (LS) mean difference were calculated from repeated measures ANCOVA mixed model with baseline value, treatment group, time, and treatment group by time interaction as fixed effects, and subjects as random effect.) · Mean difference (final values): 0.036 · 95% CI 0.001 to 0.070LS mean difference
  • Tacrolimus Then Sirolimus With Mycophenolate/Prednisone vs Tacrolimus With Mycophenolate/Prednisone · ANCOVA · p = 0.0288 (P-value and 95% CI for LS mean difference were calculated from repeated measures ANCOVA mixed model with baseline value, treatment group, time, and treatment group by time interaction as fixed effects, and subjects as random effect.) · Mean difference (final values): 0.034 · 95% CI 0.004 to 0.064LS mean difference
  • Tacrolimus Then Sirolimus With Mycophenolate/Prednisone vs Tacrolimus With Mycophenolate/Prednisone · ANCOVA · p = 0.0269 (P-value and 95% CI for LS mean difference were calculated from repeated measures ANCOVA mixed model with baseline value, treatment group, time, and treatment group by time interaction as fixed effects, and subjects as random effect.) · Mean difference (final values): 0.032 · 95% CI 0.004 to 0.060LS mean difference
  • Tacrolimus Then Sirolimus With Mycophenolate/Prednisone vs Tacrolimus With Mycophenolate/Prednisone · ANCOVA · p = 0.0970 (P-value and 95% CI for LS mean difference were calculated from repeated measures ANCOVA mixed model with baseline value, treatment group, time, and treatment group by time interaction as fixed effects, and subjects as random effect.) · Mean difference (final values): 0.028 · 95% CI -0.005 to 0.060LS mean difference
SecondaryCIMT at Pre-conversion Baseline

Mean CIMT=average of left CIMT and right CIMT.

Time frame:
Pre-conversion baseline
Reported as:
Mean · mm
CIMT at Pre-conversion Baseline
mmTacrolimus Then Sirolimus With Mycophenolate/PrednisoneTacrolimus With Mycophenolate/Prednisone
CIMT at Pre-conversion Baseline0.735 ± 0.15020.773 ± 0.1391
SecondaryChange From Pre-conversion Baseline in Carotid Plaque Roughness at 12 and 24 Months Post-transplant

Carotid plaque roughness as determined by ultrasound. Change equals (=) value at post-transplant month x minus (-) pre-conversion baseline.

Time frame:
Pre-conversion baseline, 12, and 24 months post-transplant

No measurements were reported for this outcome.

SecondaryChange From Pre-conversion Baseline in Fasting Lipid Parameters at 12, 18, 24 and 36 Months Post-transplant

Total Cholesterol (TC), Low Density Lipoprotein (LDL), High Density Lipoprotein (HDL) and Triglyceride (Tg) blood concentrations. Higher levels of TC, LDL and Tg are less desirable. Lower levels of HDL are less desirable. Change for each parameter = value at 12, 18, 24 and 36 months post-transplant - value at pre-conversion baseline.

Time frame:
Pre-conversion baseline, and 12, 18, 24 and 36 months post-transplant
Reported as:
Mean · millimole/liter (mmol/L)
Change From Pre-conversion Baseline in Fasting Lipid Parameters at 12, 18, 24 and 36 Months Post-transplant
millimole/liter (mmol/L)Tacrolimus Then Sirolimus With Mycophenolate/PrednisoneTacrolimus With Mycophenolate/Prednisone
Change in TC 12 Months post-transplant (n=23,30)0.510 ± 1.0743-0.164 ± 0.8271
Change in LDL 12 Months post-transplant (n=21,30)0.277 ± 0.8282-0.056 ± 0.5612
Change in HDL 12 Months post-transplant (n=23,30)0.059 ± 0.3009-0.053 ± 0.4417
Change in Tg 12 Months post-transplant (n=23,30)0.617 ± 1.1135-0.117 ± 0.6088
Change in TC 18 Months post-transplant (n=21,29)0.361 ± 1.07040.082 ± 1.1427
Change in LDL 18 Months post-transplant (n=20,29)0.222 ± 0.92830.138 ± 0.8600
Change in HDL 18 Months post-transplant (n=21,29)0.106 ± 0.2824-0.030 ± 0.3601
Change in Tg 18 Months post-transplant (n=21,29)0.359 ± 0.9941-0.057 ± 0.8699
Change in TC 24 Months post-transplant (n=19,27)0.240 ± 1.1375-0.008 ± 1.0813
Change in LDL 24 Months post-transplant (n=16,27)0.067 ± 0.94930.054 ± 0.8250
Change in HDL 24 Months post-transplant (n=19,27)0.067 ± 0.2485-0.019 ± 0.3552
Change in Tg 24 Months post-transplant (n=19,27)0.547 ± 1.4083-0.088 ± 0.8131
Change in TC 36 Months post-transplant (n=15,21)0.386 ± 0.4841-0.323 ± 1.0652
Change in LDL 36 Months post-transplant (n=13,21)0.027 ± 0.5619-0.257 ± 0.8248
Change in HDL 36 Months post-transplant (n=15,21)0.098 ± 0.21410.111 ± 0.3042
Change in Tg 36 Months post-transplant (n=15,21)0.527 ± 0.9968-0.385 ± 0.7824
Statistical analysis
  • Tacrolimus Then Sirolimus With Mycophenolate/Prednisone vs Tacrolimus With Mycophenolate/Prednisone · ANCOVA · p = <.0001 (P-value and 95% CI for LS mean difference were calculated from repeated measures ANCOVA mixed model with baseline value,treatment group,time and treatment group by time interaction as fixed effects,and subjects as random effect.ALPAH is unadjusted.) · Median difference (final values): 0.74 · 95% CI 0.39 to 1.09LS mean difference
  • Tacrolimus Then Sirolimus With Mycophenolate/Prednisone vs Tacrolimus With Mycophenolate/Prednisone · ANCOVA · p = 0.0022 (P-value and 95% CI for LS mean difference were calculated from repeated measures ANCOVA mixed model with baseline value,treatment group,time and treatment group by time interaction as fixed effects,and subjects as random effect.ALPAH is unadjusted.) · Mean difference (final values): 0.41 · 95% CI 0.15 to 0.67LS mean difference
  • Tacrolimus Then Sirolimus With Mycophenolate/Prednisone vs Tacrolimus With Mycophenolate/Prednisone · ANCOVA · p = 0.1612 (P-value and 95% CI for LS mean difference were calculated from repeated measures ANCOVA mixed model with baseline value,treatment group,time and treatment group by time interaction as fixed effects,and subjects as random effect.ALPAH is unadjusted.) · Mean difference (final values): 0.08 · 95% CI -0.03 to 0.19LS mean difference
  • Tacrolimus Then Sirolimus With Mycophenolate/Prednisone vs Tacrolimus With Mycophenolate/Prednisone · ANCOVA · p = 0.0005 (P-value and 95% CI for LS mean difference were calculated from repeated measures ANCOVA mixed model with baseline value,treatment group,time and treatment group by time interaction as fixed effects,and subjects as random effect.ALPAH is unadjusted.) · Mean difference (final values): 0.56 · 95% CI 0.26 to 0.86LS mean difference
  • Tacrolimus Then Sirolimus With Mycophenolate/Prednisone vs Tacrolimus With Mycophenolate/Prednisone · ANCOVA · p = 0.0006 (P-value and 95% CI for LS mean difference were calculated from repeated measures ANCOVA mixed model with baseline value,treatment group,time and treatment group by time interaction as fixed effects,and subjects as random effect.ALPAH is unadjusted.) · Mean difference (final values): 0.66 · 95% CI 0.30 to 1.02LS mean difference
  • Tacrolimus Then Sirolimus With Mycophenolate/Prednisone vs Tacrolimus With Mycophenolate/Prednisone · ANCOVA · p = 0.0126 (P-value and 95% CI for LS mean difference were calculated from repeated measures ANCOVA mixed model with baseline value,treatment group,time and treatment group by time interaction as fixed effects,and subjects as random effect.ALPAH is unadjusted.) · Mean difference (final values): 0.34 · 95% CI 0.08 to 0.61LS mean difference
  • Tacrolimus Then Sirolimus With Mycophenolate/Prednisone vs Tacrolimus With Mycophenolate/Prednisone · ANCOVA · p = 0.2380 (P-value and 95% CI for LS mean difference were calculated from repeated measures ANCOVA mixed model with baseline value,treatment group,time and treatment group by time interaction as fixed effects,and subjects as random effect.ALPAH is unadjusted.) · Mean difference (final values): 0.06 · 95% CI -0.04 to 0.17LS mean difference
  • Tacrolimus Then Sirolimus With Mycophenolate/Prednisone vs Tacrolimus With Mycophenolate/Prednisone · ANCOVA · p = 0.0003 (P-value and 95% CI for LS mean difference were calculated from repeated measures ANCOVA mixed model with baseline value,treatment group,time and treatment group by time interaction as fixed effects,and subjects as random effect.ALPAH is unadjusted.) · Mean difference (final values): 0.58 · 95% CI 0.27 to 0.88LS mean difference
  • Tacrolimus Then Sirolimus With Mycophenolate/Prednisone vs Tacrolimus With Mycophenolate/Prednisone · ANCOVA · p = 0.0065 (P-value and 95% CI for LS mean difference were calculated from repeated measures ANCOVA mixed model with baseline value,treatment group,time and treatment group by time interaction as fixed effects,and subjects as random effect.ALPAH is unadjusted.) · Mean difference (final values): 0.59 · 95% CI 0.17 to 1.00LS mean difference
  • Tacrolimus Then Sirolimus With Mycophenolate/Prednisone vs Tacrolimus With Mycophenolate/Prednisone · ANCOVA · p = 0.0845 (P-value and 95% CI for LS mean difference were calculated from repeated measures ANCOVA mixed model with baseline value,treatment group,time and treatment group by time interaction as fixed effects,and subjects as random effect.ALPAH is unadjusted.) · Mean difference (final values): 0.28 · 95% CI -0.04 to 0.60LS mean difference
  • Tacrolimus Then Sirolimus With Mycophenolate/Prednisone vs Tacrolimus With Mycophenolate/Prednisone · ANCOVA · p = 0.3742 (P-value and 95% CI for LS mean difference were calculated from repeated measures ANCOVA mixed model with baseline value,treatment group,time and treatment group by time interaction as fixed effects,and subjects as random effect.ALPAH is unadjusted.) · Mean difference (final values): 0.05 · 95% CI -0.06 to 0.16LS mean difference
  • Tacrolimus Then Sirolimus With Mycophenolate/Prednisone vs Tacrolimus With Mycophenolate/Prednisone · ANCOVA · p = 0.0006 (P-value and 95% CI for LS mean difference were calculated from repeated measures ANCOVA mixed model with baseline value,treatment group,time and treatment group by time interaction as fixed effects,and subjects as random effect.ALPAH is unadjusted.) · Mean difference (final values): 0.59 · 95% CI 0.27 to 0.92LS mean difference
  • Tacrolimus Then Sirolimus With Mycophenolate/Prednisone vs Tacrolimus With Mycophenolate/Prednisone · ANCOVA · p = 0.1488 (P-value and 95% CI for LS mean difference were calculated from repeated measures ANCOVA mixed model with baseline value,treatment group,time and treatment group by time interaction as fixed effects,and subjects as random effect.ALPAH is unadjusted.) · Mean difference (final values): 0.44 · 95% CI -0.16 to 1.03LS mean difference
  • Tacrolimus Then Sirolimus With Mycophenolate/Prednisone vs Tacrolimus With Mycophenolate/Prednisone · ANCOVA · p = 0.5460 (P-value and 95% CI for LS mean difference were calculated from repeated measures ANCOVA mixed model with baseline value,treatment group,time and treatment group by time interaction as fixed effects,and subjects as random effect.ALPAH is unadjusted.) · Mean difference (final values): 0.14 · 95% CI -0.33 to 0.62LS mean difference
  • Tacrolimus Then Sirolimus With Mycophenolate/Prednisone vs Tacrolimus With Mycophenolate/Prednisone · ANCOVA · p = 0.7511 (P-value and 95% CI for LS mean difference were calculated from repeated measures ANCOVA mixed model with baseline value,treatment group,time and treatment group by time interaction as fixed effects,and subjects as random effect.ALPAH is unadjusted.) · Mean difference (final values): 0.02 · 95% CI -0.12 to 0.16LS mean difference
  • Tacrolimus Then Sirolimus With Mycophenolate/Prednisone vs Tacrolimus With Mycophenolate/Prednisone · ANCOVA · p = 0.0048 (P-value and 95% CI for LS mean difference were calculated from repeated measures ANCOVA mixed model with baseline value,treatment group,time and treatment group by time interaction as fixed effects,and subjects as random effect.ALPAH is unadjusted.) · Mean difference (final values): 0.63 · 95% CI 0.20 to 1.06LS mean difference
SecondaryChange From Pre-conversion Baseline in Glucose at Months 12, 24 and 36 Post-transplant

Fasting plasma glucose. Change = value at month x post-transplant - pre-conversion baseline values.

Time frame:
Pre-conversion baseline, 12, 24 and 36 months post-transplant
Reported as:
Mean · mmol/L
Change From Pre-conversion Baseline in Glucose at Months 12, 24 and 36 Post-transplant
mmol/LTacrolimus Then Sirolimus With Mycophenolate/PrednisoneTacrolimus With Mycophenolate/Prednisone
Change at 12 Months post-transplant (n=23,33)0.606 ± 2.9461-0.083 ± 1.7377
Change at 24 Months post-transplant (n=19,31)0.832 ± 2.2068-0.076 ± 2.3982
Change at 36 Months post-transplant (n=14,22)0.686 ± 2.3559-0.214 ± 1.8239
Statistical analysis
  • Tacrolimus Then Sirolimus With Mycophenolate/Prednisone vs Tacrolimus With Mycophenolate/Prednisone · ANCOVA · p = 0.1757 (P-value and 95% CI for LS mean difference were calculated from repeated measures ANCOVA mixed model with baseline value,treatment group,time and treatment group by time interaction as fixed effects,and subjects as random effect.ALPAH is unadjusted.) · Mean difference (final values): 0.78 · 95% CI -0.36 to 1.91LS mean difference
  • Tacrolimus Then Sirolimus With Mycophenolate/Prednisone vs Tacrolimus With Mycophenolate/Prednisone · ANCOVA · p = 0.0509 (P-value and 95% CI for LS mean difference were calculated from repeated measures ANCOVA mixed model with baseline value,treatment group,time and treatment group by time interaction as fixed effects,and subjects as random effect.ALPAH is unadjusted.) · Mean difference (final values): 0.94 · 95% CI -0.00 to 1.89LS mean difference
  • Tacrolimus Then Sirolimus With Mycophenolate/Prednisone vs Tacrolimus With Mycophenolate/Prednisone · ANCOVA · p = 0.0683 (P-value and 95% CI for LS mean difference were calculated from repeated measures ANCOVA mixed model with baseline value,treatment group,time and treatment group by time interaction as fixed effects,and subjects as random effect.ALPAH is unadjusted.) · Mean difference (final values): 1.11 · 95% CI -0.09 to 2.31LS mean difference
SecondaryChange From Pre-conversion Baseline in Insulin at Months 12, 24, and 36 Post-transplant

Fasting insulin. Change = value at month x post-transplant - pre-conversion baseline.

Time frame:
Pre-conversion baseline, 12, 24 and 36 months post-transplant
Reported as:
Mean · picomole/liter (pmol/L)
Change From Pre-conversion Baseline in Insulin at Months 12, 24, and 36 Post-transplant
picomole/liter (pmol/L)Tacrolimus Then Sirolimus With Mycophenolate/PrednisoneTacrolimus With Mycophenolate/Prednisone
Change at 12 Months post-transplant (n=16,23)-4.549 ± 69.213917.953 ± 151.0513
Change at 24 Months post-transplant (n=13,23)-6.120 ± 124.550032.180 ± 168.4674
Change at 36 Months post-transplant (n=10,14)-22.759 ± 79.8717-2.731 ± 37.6576
Statistical analysis
  • Tacrolimus Then Sirolimus With Mycophenolate/Prednisone vs Tacrolimus With Mycophenolate/Prednisone · ANCOVA · p = 0.2741 (P-value and 95% CI for LS mean difference were calculated from repeated measures ANCOVA mixed model with baseline value,treatment group,time and treatment group by time interaction as fixed effects,and subjects as random effect.ALPAH is unadjusted.) · Mean difference (final values): -37.47 · 95% CI -105.79 to 30.85LS mean difference
  • Tacrolimus Then Sirolimus With Mycophenolate/Prednisone vs Tacrolimus With Mycophenolate/Prednisone · ANCOVA · p = 0.4865 (P-value and 95% CI for LS mean difference were calculated from repeated measures ANCOVA mixed model with baseline value,treatment group,time and treatment group by time interaction as fixed effects,and subjects as random effect.ALPAH is unadjusted.) · Mean difference (final values): -19.97 · 95% CI -77.48 to 37.53LS mean difference
  • Tacrolimus Then Sirolimus With Mycophenolate/Prednisone vs Tacrolimus With Mycophenolate/Prednisone · ANCOVA · p = 0.9339 (P-value and 95% CI for LS mean difference were calculated from repeated measures ANCOVA mixed model with baseline value,treatment group,time and treatment group by time interaction as fixed effects,and subjects as random effect.ALPAH is unadjusted.) · Mean difference (final values): -2.48 · 95% CI -62.54 to 57.59LS mean difference
SecondaryChange From Pre-conversion Baseline in Glycosylated Hemoglobin(HbA1C) at Months 12, 24, and 36 Post-transplant

HbA1C, change = value at month x post-transplant - pre-conversion baseline.

Time frame:
Pre-conversion baseline, 12, 24 and 36 months post-transplant
Reported as:
Mean · percentage of glucose
Change From Pre-conversion Baseline in Glycosylated Hemoglobin(HbA1C) at Months 12, 24, and 36 Post-transplant
percentage of glucoseTacrolimus Then Sirolimus With Mycophenolate/PrednisoneTacrolimus With Mycophenolate/Prednisone
Change at 12 Months post-transplant (n=23,26)0.008 ± 0.01760.001 ± 0.0175
Change at 24 Months post-transplant (n=17,25)0.009 ± 0.01610.006 ± 0.0200
Change at 36 Months post-transplant (n=14,16)0.012 ± 0.0208-0.001 ± 0.0232
Statistical analysis
  • Tacrolimus Then Sirolimus With Mycophenolate/Prednisone vs Tacrolimus With Mycophenolate/Prednisone · ANCOVA · p = 0.4892 (P-value and 95% CI for LS mean difference were calculated from repeated measures ANCOVA mixed model with baseline value,treatment group,time and treatment group by time interaction as fixed effects,and subjects as random effect.ALPAH is unadjusted.) · Mean difference (final values): 0.003 · 95% CI -0.005 to 0.011LS mean difference
  • Tacrolimus Then Sirolimus With Mycophenolate/Prednisone vs Tacrolimus With Mycophenolate/Prednisone · ANCOVA · p = 0.0514 (P-value and 95% CI for LS mean difference were calculated from repeated measures ANCOVA mixed model with baseline value,treatment group,time and treatment group by time interaction as fixed effects,and subjects as random effect.ALPAH is unadjusted.) · Mean difference (final values): 0.006 · 95% CI -0.000 to 0.012LS mean difference
  • Tacrolimus Then Sirolimus With Mycophenolate/Prednisone vs Tacrolimus With Mycophenolate/Prednisone · ANCOVA · p = 0.1180 (P-value and 95% CI for LS mean difference were calculated from repeated measures ANCOVA mixed model with baseline value,treatment group,time and treatment group by time interaction as fixed effects,and subjects as random effect.ALPAH is unadjusted.) · Mean difference (final values): 0.009 · 95% CI -0.002 to 0.020LS mean difference
SecondaryChange From Pre-conversion Baseline in Adiponectin at Months 12, 24 and 36 Post-transplant

Adiponectin is a biomarker for cardiovascular disease and atherosclerosis risk. A higher level indicates less risk. Change = month x post-transplant values - pre-conversion baseline values.

Time frame:
Pre-conversion baseline, 12, 24 and 36 months post-transplant
Reported as:
Mean · microgram per milliliter (µg/mL)
Change From Pre-conversion Baseline in Adiponectin at Months 12, 24 and 36 Post-transplant
microgram per milliliter (µg/mL)Tacrolimus Then Sirolimus With Mycophenolate/PrednisoneTacrolimus With Mycophenolate/Prednisone
Change at 12 Months post-transplant (n=23,33)5.352 ± 5.8935-2.205 ± 8.2503
Change at 24 Months post-transplant (n=18,31)2.244 ± 7.3628-0.267 ± 6.6144
Change at 36 Months post-transplant (n=15,22)1.487 ± 6.0933-1.413 ± 8.8053
Statistical analysis
  • Tacrolimus Then Sirolimus With Mycophenolate/Prednisone vs Tacrolimus With Mycophenolate/Prednisone · ANCOVA · p = 0.0016 (P-value and 95% CI for LS mean difference were calculated from repeated measures ANCOVA mixed model with baseline value,treatment group,time and treatment group by time interaction as fixed effects,and subjects as random effect.ALPAH is unadjusted.) · Mean difference (final values): 5.56 · 95% CI 2.20 to 8.93LS mean difference
  • Tacrolimus Then Sirolimus With Mycophenolate/Prednisone vs Tacrolimus With Mycophenolate/Prednisone · ANCOVA · p = 0.0091 (P-value and 95% CI for LS mean difference were calculated from repeated measures ANCOVA mixed model with baseline value,treatment group,time and treatment group by time interaction as fixed effects,and subjects as random effect.ALPAH is unadjusted.) · Mean difference (final values): 3.91 · 95% CI 1.01 to 6.80LS mean difference
  • Tacrolimus Then Sirolimus With Mycophenolate/Prednisone vs Tacrolimus With Mycophenolate/Prednisone · ANCOVA · p = 0.2468 (P-value and 95% CI for LS mean difference were calculated from repeated measures ANCOVA mixed model with baseline value,treatment group,time and treatment group by time interaction as fixed effects,and subjects as random effect.ALPAH is unadjusted.) · Mean difference (final values): 2.25 · 95% CI -1.60 to 6.10LS mean difference
SecondaryChange From Pre-conversion Baseline in High Sensitivity C-Reactive Protein (hsCRP) at Months 12, 24 and 36 Post-transplant.

hsCRP is a biomarker of cardiovascular disease and atherosclerosis risk. A higher level indicates a greater risk. Change = month x post-transplant values - pre-conversion baseline values.

Time frame:
Pre-conversion baseline, 12, 24 and 36 months post-transplant
Reported as:
Mean · mg/L
Change From Pre-conversion Baseline in High Sensitivity C-Reactive Protein (hsCRP) at Months 12, 24 and 36 Post-transplant.
mg/LTacrolimus Then Sirolimus With Mycophenolate/PrednisoneTacrolimus With Mycophenolate/Prednisone
Change at 12 Months post-transplant (n=23,33)1.611 ± 9.72191.379 ± 6.7680
Change at 24 Months post-transplant (n=18,31)-0.563 ± 4.83471.723 ± 7.6259
Change at 36 Months post-transplant (n=15,22)0.336 ± 11.35373.164 ± 12.5660
Statistical analysis
  • Tacrolimus Then Sirolimus With Mycophenolate/Prednisone vs Tacrolimus With Mycophenolate/Prednisone · ANCOVA · p = 0.5282 (P-value and 95% CI for LS mean difference were calculated from repeated measures ANCOVA mixed model with baseline value,treatment group,time and treatment group by time interaction as fixed effects,and subjects as random effect.ALPAH is unadjusted.) · Mean difference (final values): 0.95 · 95% CI -2.05 to 3.94LS mean difference
  • Tacrolimus Then Sirolimus With Mycophenolate/Prednisone vs Tacrolimus With Mycophenolate/Prednisone · ANCOVA · p = 0.5057 (P-value and 95% CI for LS mean difference were calculated from repeated measures ANCOVA mixed model with baseline value,treatment group,time and treatment group by time interaction as fixed effects,and subjects as random effect.ALPAH is unadjusted.) · Mean difference (final values): 1.27 · 95% CI -2.53 to 5.07LS mean difference
  • Tacrolimus Then Sirolimus With Mycophenolate/Prednisone vs Tacrolimus With Mycophenolate/Prednisone · ANCOVA · p = 0.5701 (P-value and 95% CI for LS mean difference were calculated from repeated measures ANCOVA mixed model with baseline value,treatment group,time and treatment group by time interaction as fixed effects,and subjects as random effect.ALPAH is unadjusted.) · Mean difference (final values): 1.59 · 95% CI -4.00 to 7.18LS mean difference
SecondaryChange From Pre-conversion Baseline in Tumor Necrosis Factor Alpha (TNF-alpha) at Months 12, 24 and 36 Post-transplant

TNF-alpha is a biomarker for cardiovascular disease and atherosclerosis risk. A higher level indicates a greater risk. Change = month x post-transplant values - pre-conversion baseline values.

Time frame:
Pre-conversion baseline, 12, 24 and 36 months post-transplant
Reported as:
Mean · pg/mL
Change From Pre-conversion Baseline in Tumor Necrosis Factor Alpha (TNF-alpha) at Months 12, 24 and 36 Post-transplant
pg/mLTacrolimus Then Sirolimus With Mycophenolate/PrednisoneTacrolimus With Mycophenolate/Prednisone
Change at 12 Months post-transplant (n=23,32)0.991 ± 6.34620.000 ± 0.0000
Change at 24 Months post-transplant (n=18,30)-0.367 ± 1.55801.894 ± 10.3720
Change at 36 Months post-transplant (n=15,22)-0.441 ± 1.70670.000 ± 0.0000
SecondaryChange From Pre-conversion Baseline in Endothelin-1 at Months 12, 24 and 36 Post-transplant

Endothelin-1 is a biomarker for cardiovascular disease and atherosclerosis risk. A higher level indicates greater risk. Change = month x post-transplant values - pre-conversion baseline values.

Time frame:
Pre-conversion baseline, 12, 24 and 36 months post-transplant
Reported as:
Mean · pg/mL
Change From Pre-conversion Baseline in Endothelin-1 at Months 12, 24 and 36 Post-transplant
pg/mLTacrolimus Then Sirolimus With Mycophenolate/PrednisoneTacrolimus With Mycophenolate/Prednisone
Change at 12 Months post-transplant (n=22,30)0.294 ± 0.49750.028 ± 0.4020
Change at 24 Months post-transplant (n=18,30)0.426 ± 0.53760.138 ± 0.8367
Change at 36 Months post-transplant (n=14,22)0.411 ± 0.7316-0.104 ± 0.7767
Statistical analysis
  • Tacrolimus Then Sirolimus With Mycophenolate/Prednisone vs Tacrolimus With Mycophenolate/Prednisone · ANCOVA · p = 0.0280 (P-value and 95% CI for LS mean difference were calculated from repeated measures ANCOVA mixed model with baseline value,treatment group,time and treatment group by time interaction as fixed effects,and subjects as random effect.ALPAH is unadjusted.) · Mean difference (final values): 0.26 · 95% CI 0.03 to 0.48
  • Tacrolimus Then Sirolimus With Mycophenolate/Prednisone vs Tacrolimus With Mycophenolate/Prednisone · ANCOVA · p = 0.0190 (P-value and 95% CI for LS mean difference were calculated from repeated measures ANCOVA mixed model with baseline value,treatment group,time and treatment group by time interaction as fixed effects,and subjects as random effect.ALPAH is unadjusted.) · Mean difference (final values): 0.26 · 95% CI 0.04 to 0.48
  • Tacrolimus Then Sirolimus With Mycophenolate/Prednisone vs Tacrolimus With Mycophenolate/Prednisone · ANCOVA · p = 0.1182 (P-value and 95% CI for LS mean difference were calculated from repeated measures ANCOVA mixed model with baseline value,treatment group,time and treatment group by time interaction as fixed effects,and subjects as random effect.ALPAH is unadjusted.) · Mean difference (final values): 0.27 · 95% CI -0.07 to 0.60
SecondaryChange From Pre-conversion Baseline in Interleukin-6 (IL-6) at Months 12, 24 and 36 Post-transplant

IL-6 is a biomarker for cardiovascular disease and atherosclerosis risk. A higher level indicates a greater risk. Change = month x post-transplant values - pre-conversion values.

Time frame:
Pre-conversion baseline, 12, 24 and 36 months post-transplant
Reported as:
Mean · pg/mL
Change From Pre-conversion Baseline in Interleukin-6 (IL-6) at Months 12, 24 and 36 Post-transplant
pg/mLTacrolimus Then Sirolimus With Mycophenolate/PrednisoneTacrolimus With Mycophenolate/Prednisone
Change at 12 Months post-transplant (n=23,32)-0.239 ± 3.68200.463 ± 3.8100
Change at 24 Months post-transplant (n=18,29)0.128 ± 6.93150.783 ± 4.7295
Change at 36 Months post-transplant (n=15,22)-0.800 ± 3.82700.164 ± 6.4529
Statistical analysis
  • Tacrolimus Then Sirolimus With Mycophenolate/Prednisone vs Tacrolimus With Mycophenolate/Prednisone · ANCOVA · p = 0.7361 (P-value and 95% CI for LS mean difference were calculated from repeated measures ANCOVA mixed model with baseline value,treatment group,time and treatment group by time interaction as fixed effects,and subjects as random effect.ALPAH is unadjusted.) · Mean difference (final values): -0.30 · 95% CI -2.09 to 1.49LS mean difference
  • Tacrolimus Then Sirolimus With Mycophenolate/Prednisone vs Tacrolimus With Mycophenolate/Prednisone · ANCOVA · p = 0.5549 (P-value and 95% CI for LS mean difference were calculated from repeated measures ANCOVA mixed model with baseline value,treatment group,time and treatment group by time interaction as fixed effects,and subjects as random effect.ALPAH is unadjusted.) · Mean difference (final values): -0.53 · 95% CI -2.32 to 1.26LS mean difference
  • Tacrolimus Then Sirolimus With Mycophenolate/Prednisone vs Tacrolimus With Mycophenolate/Prednisone · ANCOVA · p = 0.6058 (P-value and 95% CI for LS mean difference were calculated from repeated measures ANCOVA mixed model with baseline value,treatment group,time and treatment group by time interaction as fixed effects,and subjects as random effect.ALPAH is unadjusted.) · Mean difference (final values): -0.76 · 95% CI -3.69 to 2.17LS mean difference
SecondaryChange From Pre-conversion Baseline in Homocysteine at Months 12, 24 and 36 Post-transplant

Homocysteine is a biomarker for cardiovascular disease and atherosclerosis risk. A higher level indicates a greater risk. Change = month x post-transplant values - pre-conversion baseline values.

Time frame:
Pre-conversion baseline, 12, 24 and 36 months post-transplant
Reported as:
Mean · micromole/liter (µmol/L)
Change From Pre-conversion Baseline in Homocysteine at Months 12, 24 and 36 Post-transplant
micromole/liter (µmol/L)Tacrolimus Then Sirolimus With Mycophenolate/PrednisoneTacrolimus With Mycophenolate/Prednisone
Change at 12 Months post-transplant (n=23,33)1.278 ± 3.55720.530 ± 4.6244
Change at 24 Months post-transplant (n=19,31)1.316 ± 4.53732.158 ± 5.8978
Change at 36 Months post-transplant (n=15,22)1.087 ± 4.66412.459 ± 5.3116
Statistical analysis
  • Tacrolimus Then Sirolimus With Mycophenolate/Prednisone vs Tacrolimus With Mycophenolate/Prednisone · ANCOVA · p = 0.5902 (P-value and 95% CI for LS mean difference were calculated from repeated measures ANCOVA mixed model with baseline value,treatment group,time and treatment group by time interaction as fixed effects,and subjects as random effect.ALPAH is unadjusted.) · Mean difference (final values): 0.60 · 95% CI -1.63 to 2.84LS mean difference
  • Tacrolimus Then Sirolimus With Mycophenolate/Prednisone vs Tacrolimus With Mycophenolate/Prednisone · ANCOVA · p = 0.7536 (P-value and 95% CI for LS mean difference were calculated from repeated measures ANCOVA mixed model with baseline value,treatment group,time and treatment group by time interaction as fixed effects,and subjects as random effect.ALPAH is unadjusted.) · Mean difference (final values): -0.36 · 95% CI -2.68 to 1.95LS mean difference
  • Tacrolimus Then Sirolimus With Mycophenolate/Prednisone vs Tacrolimus With Mycophenolate/Prednisone · ANCOVA · p = 0.4066 (P-value and 95% CI for LS mean difference were calculated from repeated measures ANCOVA mixed model with baseline value,treatment group,time and treatment group by time interaction as fixed effects,and subjects as random effect.ALPAH is unadjusted.) · Mean difference (final values): -1.33 · 95% CI -4.53 to 1.86LS mean difference
SecondaryChange From Pre-conversion Baseline in Lipoprotein(a) at Months 12, 24 and 36 Post-transplant

Lipoprotein(a) is a biomarker for cardiovascular disease and atherosclerosis risk. A higher level indicates a greater risk. Change = month x post-transplant values - pre-conversion baseline values.

Time frame:
Pre-conversion baseline, 12, 24 and 36 months post-transplant
Reported as:
Mean · milligram per deciliter (mg/dL)
Change From Pre-conversion Baseline in Lipoprotein(a) at Months 12, 24 and 36 Post-transplant
milligram per deciliter (mg/dL)Tacrolimus Then Sirolimus With Mycophenolate/PrednisoneTacrolimus With Mycophenolate/Prednisone
Change at 12 Months post-transplant (n=23,30)13.496 ± 23.3557-11.680 ± 77.1386
Change at 24 Months post-transplant (n=18,26)12.517 ± 36.88686.073 ± 31.5608
Change at 36 Months post-transplant (n=13,17)11.885 ± 49.48686.547 ± 22.0615
Statistical analysis
  • Tacrolimus Then Sirolimus With Mycophenolate/Prednisone vs Tacrolimus With Mycophenolate/Prednisone · ANCOVA · p = 0.3678 (P-value and 95% CI for LS mean difference were calculated from repeated measures ANCOVA mixed model with baseline value,treatment group,time and treatment group by time interaction as fixed effects,and subjects as random effect.ALPAH is unadjusted.) · Mean difference (final values): 9.47 · 95% CI -11.46 to 30.40LS mean difference
  • Tacrolimus Then Sirolimus With Mycophenolate/Prednisone vs Tacrolimus With Mycophenolate/Prednisone · ANCOVA · p = 0.2179 (P-value and 95% CI for LS mean difference were calculated from repeated measures ANCOVA mixed model with baseline value,treatment group,time and treatment group by time interaction as fixed effects,and subjects as random effect.ALPAH is unadjusted.) · Mean difference (final values): 10.72 · 95% CI -6.53 to 27.97LS mean difference
  • Tacrolimus Then Sirolimus With Mycophenolate/Prednisone vs Tacrolimus With Mycophenolate/Prednisone · ANCOVA · p = 0.3663 (P-value and 95% CI for LS mean difference were calculated from repeated measures ANCOVA mixed model with baseline value,treatment group,time and treatment group by time interaction as fixed effects,and subjects as random effect.ALPAH is unadjusted.) · Mean difference (final values): 11.96 · 95% CI -14.39 to 38.32LS mean difference
SecondaryChange From Pre-conversion Baseline in Fibrinogen at Months 12, 24 and 36 Post-transplant

Fibrinogen is a biomarker for cardiovascular disease and atherosclerosis risk. A higher level indicates a greater risk. Change = month x post-transplant values - pre-conversion baseline values.

Time frame:
Pre-conversion baseline, 12, 24 and 36 months post-transplant
Reported as:
Mean · gram per liter (g/L)
Change From Pre-conversion Baseline in Fibrinogen at Months 12, 24 and 36 Post-transplant
gram per liter (g/L)Tacrolimus Then Sirolimus With Mycophenolate/PrednisoneTacrolimus With Mycophenolate/Prednisone
Change at 12 Months post-transplant (n=22,31)0.62 ± 0.7780.20 ± 0.769
Change at 24 Months post-transplant (n=19,29)0.45 ± 0.7770.33 ± 0.741
Change at 36 Months post-transplant (n=14,20)0.40 ± 0.5570.21 ± 0.740
Statistical analysis
  • Tacrolimus Then Sirolimus With Mycophenolate/Prednisone vs Tacrolimus With Mycophenolate/Prednisone · ANCOVA · p = 0.0410 (P-value and 95% CI for LS mean difference were calculated from repeated measures ANCOVA mixed model with baseline value,treatment group,time and treatment group by time interaction as fixed effects,and subjects as random effect.ALPAH is unadjusted.) · Mean difference (final values): 0.4 · 95% CI 0.0 to 0.8LS mean difference
  • Tacrolimus Then Sirolimus With Mycophenolate/Prednisone vs Tacrolimus With Mycophenolate/Prednisone · ANCOVA · p = 0.0275 (P-value and 95% CI for LS mean difference were calculated from repeated measures ANCOVA mixed model with baseline value,treatment group,time and treatment group by time interaction as fixed effects,and subjects as random effect.ALPAH is unadjusted.) · Mean difference (final values): 0.3 · 95% CI 0.0 to 0.6LS mean difference
  • Tacrolimus Then Sirolimus With Mycophenolate/Prednisone vs Tacrolimus With Mycophenolate/Prednisone · ANCOVA · p = 0.1841 (P-value and 95% CI for LS mean difference were calculated from repeated measures ANCOVA mixed model with baseline value,treatment group,time and treatment group by time interaction as fixed effects,and subjects as random effect.ALPAH is unadjusted.) · Mean difference (final values): 0.2 · 95% CI -0.1 to 0.6LS mean difference
SecondaryChange From Pre-conversion Baseline in Vitamin B12 at Months 12, 24 and 36 Post-transplant

Vitamin B12 is a biomarker for cardiovascular disease and atherosclerosis risk. A lower level indicates a greater risk. Change = month x post-transplant values - pre-conversion values.

Time frame:
Pre-conversion baseline, 12, 24 and 36 months post-transplant
Reported as:
Mean · pmol/L
Change From Pre-conversion Baseline in Vitamin B12 at Months 12, 24 and 36 Post-transplant
pmol/LTacrolimus Then Sirolimus With Mycophenolate/PrednisoneTacrolimus With Mycophenolate/Prednisone
Change at 12 Months post-transplant (n=21,33)-10.21 ± 161.662-11.38 ± 146.530
Change at 24 Months post-transplant (n=19,29)-36.23 ± 88.910-27.46 ± 134.595
Change at 36 Months post-transplant (n=14,21)-40.00 ± 135.353-46.39 ± 183.283
Statistical analysis
  • Tacrolimus Then Sirolimus With Mycophenolate/Prednisone vs Tacrolimus With Mycophenolate/Prednisone · ANCOVA · p = 0.0797 (P-value and 95% CI for LS mean difference were calculated from repeated measures ANCOVA mixed model with baseline value,treatment group,time and treatment group by time interaction as fixed effects,and subjects as random effect.ALPAH is unadjusted.) · Mean difference (final values): -51.3 · 95% CI -108.9 to 6.3LS mean difference
  • Tacrolimus Then Sirolimus With Mycophenolate/Prednisone vs Tacrolimus With Mycophenolate/Prednisone · ANCOVA · p = 0.2341 (P-value and 95% CI for LS mean difference were calculated from repeated measures ANCOVA mixed model with baseline value,treatment group,time and treatment group by time interaction as fixed effects,and subjects as random effect.ALPAH is unadjusted.) · Mean difference (final values): -33.3 · 95% CI -88.7 to 22.2LS mean difference
  • Tacrolimus Then Sirolimus With Mycophenolate/Prednisone vs Tacrolimus With Mycophenolate/Prednisone · ANCOVA · p = 0.6854 (P-value and 95% CI for LS mean difference were calculated from repeated measures ANCOVA mixed model with baseline value,treatment group,time and treatment group by time interaction as fixed effects,and subjects as random effect.ALPAH is unadjusted.) · Mean difference (final values): -15.2 · 95% CI -90.3 to 59.8LS mean difference
SecondaryChange From Pre-conversion Baseline in Uric Acid at Months 12, 24 and 36 Post-transplant

Uric Acid is a biomarker for cardiovascular disease and atherosclerosis risk. A higher level indicates a greater risk. Change = month x post-transplant values - pre-conversion baseline values.

Time frame:
Pre-conversion baseline, 12, 24 and 36 months post-transplant
Reported as:
Mean · µmol/L
Change From Pre-conversion Baseline in Uric Acid at Months 12, 24 and 36 Post-transplant
µmol/LTacrolimus Then Sirolimus With Mycophenolate/PrednisoneTacrolimus With Mycophenolate/Prednisone
Change at 12 Months post-transplant (n=23,33)-51.53 ± 68.98711.10 ± 89.871
Change at 24 Months post-transplant (n=19,31)-29.02 ± 93.3503.89 ± 85.439
Change at 36 Months post-transplant (n=15,22)-19.03 ± 83.162-0.58 ± 99.831
Statistical analysis
  • Tacrolimus Then Sirolimus With Mycophenolate/Prednisone vs Tacrolimus With Mycophenolate/Prednisone · ANCOVA · p = 0.0002 (P-value and 95% CI for LS mean difference were calculated from repeated measures ANCOVA mixed model with baseline value,treatment group,time and treatment group by time interaction as fixed effects,and subjects as random effect.ALPAH is unadjusted.) · Mean difference (final values): -72.8 · 95% CI -108.6 to -36.9LS mean difference
  • Tacrolimus Then Sirolimus With Mycophenolate/Prednisone vs Tacrolimus With Mycophenolate/Prednisone · ANCOVA · p = 0.0017 (P-value and 95% CI for LS mean difference were calculated from repeated measures ANCOVA mixed model with baseline value,treatment group,time and treatment group by time interaction as fixed effects,and subjects as random effect.ALPAH is unadjusted.) · Mean difference (final values): -67.6 · 95% CI -108.5 to -26.6LS mean difference
  • Tacrolimus Then Sirolimus With Mycophenolate/Prednisone vs Tacrolimus With Mycophenolate/Prednisone · ANCOVA · p = 0.0293 (P-value and 95% CI for LS mean difference were calculated from repeated measures ANCOVA mixed model with baseline value,treatment group,time and treatment group by time interaction as fixed effects,and subjects as random effect.ALPAH is unadjusted.) · Mean difference (final values): -62.3 · 95% CI -118.2 to -6.5LS mean difference
SecondaryChange From Pre-conversion Baseline in Folate at 12, 24 and 36 Months Post-transplant

Folate is a biomarker for cardiovascular disease and atherosclerosis risk. A lower level indicates a greater risk. Change = month x post-transplant values - pre-conversion baseline values.

Time frame:
Pre-conversion baseline, 12, 24 and 36 months post-transplant

No measurements were reported for this outcome.

SecondaryNumber of Participants Who Used Lipid Lowering Therapies

Participants who reported "yes" for taking lipid lowering therapies as concomitant medication.

Time frame:
From consent to conversion, from conversion to Month 12, from Months 12 to 24, and from Months 24 to 36 post-transplant
Reported as:
Number · participants
Number of Participants Who Used Lipid Lowering Therapies
participantsTacrolimus Then Sirolimus With Mycophenolate/PrednisoneTacrolimus With Mycophenolate/Prednisone
From consent to conversion1324
From conversion to Month 122229
From Months 12 to Month 242328
From Months 24 to Month 361827
Statistical analysis
  • Tacrolimus Then Sirolimus With Mycophenolate/Prednisone vs Tacrolimus With Mycophenolate/Prednisone · Fisher Exact · p = 0.2573 (P-value was calculated from 2-sided Fisher's exact test. Alpha is unadjusted.)
  • Tacrolimus Then Sirolimus With Mycophenolate/Prednisone vs Tacrolimus With Mycophenolate/Prednisone · Fisher Exact · p = 0.6386 (P-value was calculated from 2-sided Fisher's exact test. Alpha is unadjusted.)
  • Tacrolimus Then Sirolimus With Mycophenolate/Prednisone vs Tacrolimus With Mycophenolate/Prednisone · Fisher Exact · p = 0.0709 (P-value was calculated from 2-sided Fisher's exact test. Alpha is unadjusted.)
  • Tacrolimus Then Sirolimus With Mycophenolate/Prednisone vs Tacrolimus With Mycophenolate/Prednisone · Fisher Exact · p = 1.0000 (P-value was calculated from 2-sided Fisher's exact test. Alpha is unadjusted.)
SecondaryNumber of Participants Who Used Anti-hypertensive Medications

Participants who reported "yes" for taking anti-hypertensive medications as concomitant medication.

Time frame:
From consent to conversion, from conversion to Month 12, from Months 12 to 24, and from Months 24 to 36 post-transplant
Reported as:
Number · participants
Number of Participants Who Used Anti-hypertensive Medications
participantsTacrolimus Then Sirolimus With Mycophenolate/PrednisoneTacrolimus With Mycophenolate/Prednisone
From consent to conversion1930
From conversion to Month 122130
From Months 12 to Month 242130
From Months 24 to Month 361828
Statistical analysis
  • Tacrolimus Then Sirolimus With Mycophenolate/Prednisone vs Tacrolimus With Mycophenolate/Prednisone · Fisher Exact · p = 0.4286 (P-value was calculated from 2-sided Fisher's exact test. Alpha is unadjusted.)
  • Tacrolimus Then Sirolimus With Mycophenolate/Prednisone vs Tacrolimus With Mycophenolate/Prednisone · Fisher Exact · p = 1.0000 (P-value was calculated from 2-sided Fisher's exact test. Alpha is unadjusted.)
  • Tacrolimus Then Sirolimus With Mycophenolate/Prednisone vs Tacrolimus With Mycophenolate/Prednisone · Fisher Exact · p = 1.0000 (P-value was calculated from 2-sided Fisher's exact test. Alpha is unadjusted.)
  • Tacrolimus Then Sirolimus With Mycophenolate/Prednisone vs Tacrolimus With Mycophenolate/Prednisone · Fisher Exact · p = 1.0000 (P-value was calculated from 2-sided Fisher's exact test. Alpha is unadjusted.)
SecondaryAnnual Rate of Change in TPV From Pre-conversion Baseline to 18, 24 and 36 Months Post Transplant

Within-subject annual change rate in TPV in the left and right distal common carotid arteries from the pre-conversion baseline to 18, 24 and 36 months post kidney transplant as determined by ultrasound. Annual change rate equals (=) (TPV at month 18, 24 and 36 post-transplant minus \[-\] TPV at pre-conversion baseline) divided (/) by imaging interval in years. TPV is the sum of assessment in left and right distal common carotid arteries.

Time frame:
Pre-conversion baseline, and 18, 24 and 36 months post-transplant
Reported as:
Mean · mmˆ3/year
Annual Rate of Change in TPV From Pre-conversion Baseline to 18, 24 and 36 Months Post Transplant
mmˆ3/yearTacrolimus Then Sirolimus With Mycophenolate/PrednisoneTacrolimus With Mycophenolate/Prednisone
Month 18 post-transplant (n=12,12)17.15 ± 92.15119.71 ± 44.734
Month 24 post-transplant (n=11,14)25.28 ± 67.3939.10 ± 39.707
Month 36 post-transplant (n=7,11)6.62 ± 66.2408.98 ± 25.505
Statistical analysis
  • Tacrolimus Then Sirolimus With Mycophenolate/Prednisone vs Tacrolimus With Mycophenolate/Prednisone · ANCOVA · p = 0.2718 (P-value and 95% CI for LS mean difference were calculated from repeated measures ANCOVA mixed model with baseline value, treatment group, time, and treatment group by time interaction as fixed effects, and subjects as random effect.) · Mean difference (final values): -18.0 · 95% CI -50.7 to 14.7LS mean difference
  • Tacrolimus Then Sirolimus With Mycophenolate/Prednisone vs Tacrolimus With Mycophenolate/Prednisone · ANCOVA · p = 0.2729 (P-value and 95% CI for LS mean difference were calculated from repeated measures ANCOVA mixed model with baseline value, treatment group, time, and treatment group by time interaction as fixed effects, and subjects as random effect.) · Mean difference (final values): -14.7 · 95% CI -41.6 to 12.1LS mean difference
  • Tacrolimus Then Sirolimus With Mycophenolate/Prednisone vs Tacrolimus With Mycophenolate/Prednisone · ANCOVA · p = 0.2902 (P-value and 95% CI for LS mean difference were calculated from repeated measures ANCOVA mixed model with baseline value, treatment group, time, and treatment group by time interaction as fixed effects, and subjects as random effect.) · Mean difference (final values): -8.2 · 95% CI -23.8 to 7.3LS mean difference

Adverse events

Collected over From post-conversion to the end of the study (Month 36 post-transplant). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tacrolimus Then Sirolimus With Mycophenolate/Prednisone—17/37 (45.9%)36/37 (97.3%)
Tacrolimus With Mycophenolate/Prednisone—21/35 (60%)33/35 (94.3%)
Most frequent serious events
Showing 10 of 49
Most frequent serious events
EventTacrolimus Then Sirolimus With Mycophenolate/PrednisoneTacrolimus With Mycophenolate/Prednisone
INFECTIONGeneral disorders2/373/35
CELLULITISGeneral disorders0/372/35
HERNIAGeneral disorders1/372/35
IMMUNE SYSTEM DISORDERGeneral disorders2/372/35
VIRAL INFECTIONGeneral disorders2/372/35
ARTERIOSCLEROSISCardiac disorders0/372/35
GASTROINTESTINAL HEMORRHAGEGastrointestinal disorders0/372/35
VOMITINGGastrointestinal disorders0/372/35
PNEUMONIARespiratory, thoracic and mediastinal disorders1/372/35
SINUSITISRespiratory, thoracic and mediastinal disorders0/372/35
Most frequent other events
Showing 10 of 80
Most frequent other events
EventTacrolimus Then Sirolimus With Mycophenolate/PrednisoneTacrolimus With Mycophenolate/Prednisone
HYPERLIPEMIAMetabolism and nutrition disorders14/375/35
PERIPHERAL EDEMAMetabolism and nutrition disorders13/376/35
ACCIDENTAL INJURYGeneral disorders9/375/35
INFECTIONGeneral disorders9/377/35
HYPERCHOLESTEREMIAMetabolism and nutrition disorders9/372/35
ALBUMINURIARenal and urinary disorders9/372/35
BACK PAINGeneral disorders4/377/35
PAINGeneral disorders7/377/35
VIRAL INFECTIONGeneral disorders4/377/35
ANEMIABlood and lymphatic system disorders4/377/35

Baseline characteristics

Age Continuous
Age Continuous(years)Tacrolimus Then Sirolimus With Mycophenolate/PrednisoneTacrolimus With Mycophenolate/PrednisoneTotal
Mean55.8 ± 11.1155.5 ± 11.0855.7 ± 11.02
Sex: Female, Male
Sex: Female, Male(Participants)Tacrolimus Then Sirolimus With Mycophenolate/PrednisoneTacrolimus With Mycophenolate/PrednisoneTotal
Female11920
Male262652
08

Study locations

8 sites
  • Pfizer Investigational Site
    Rochester, New York 14642, United States
  • Pfizer Investigational Site
    Calgary, Alberta T2N 2T9, Canada
  • Pfizer Investigational Site
    Edmonton, Alberta T6G 2B7, Canada
  • Pfizer Investigational Site
    Hamilton, Ontario L8N 4A6, Canada
  • Pfizer Investigational Site
    London, Ontario N6A 5A5, Canada
  • Pfizer Investigational Site
    Toronto, Ontario M5B 1W8, Canada
  • Pfizer Investigational Site
    Toronto, Ontario M5C 2T2, Canada
  • Pfizer Investigational Site
    Montreal, Quebec H1T 2M4, Canada
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2006, a primary completion of Dec 2010 and a completion of Jan 2012. It does not say whether these dates are actual or estimated.

Results were first posted in May 2012, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 3, 2006
First posted
Apr 5, 2006
Start
Apr 2006
Primary completionActual
Dec 2010
CompletionActual
Jan 2012
Results first posted
May 24, 2012
Last update
Sep 23, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 23, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00311311
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Apr 5, 2006
Start date
Apr 2006
Primary completion
Dec 2010
Completion
Jan 2012
Results posted
May 24, 2012
Last update
Sep 23, 2013

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sirolimus

Start the discussion